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Abstract
Background: Infection with human immunodeficiency virus type-1 (HIV-1) requires binding of the
viral envelope gp120 to CD4 and to the CXCR4 coreceptor. Both, gp120 and CXCR4 are subject
to N-glycosylation. Here we investigated the influence of the N-linked glycans g1 and g2 present
on CXCR4 for HIV-1 infection.
Methods: The two CXCR4 N-glycosylation sites g1 (NYT) and g2 (NVS) were mutated by
changing the first or third amino acids N or T/S to Q and A respectively (g1; N11Q or T13A; g2,
N176Q or S178A). Human osteosarcoma cells (GHOST) expressing human CD4 and the various
CXCR4 glycosylation mutants were tested for infection using NL4-3-based viruses with X4, R5 or
R5X4-tropism differing only in the V3 loop region.
Results: All constructed cell lines expressing the various CXCR4 glycomutants showed similar
permissiveness for the X4-monotropic virus and no change in the coreceptor specificity that allows
infection of a CCR5-dependent R5-monotropic virus. Interestingly, the removal of glycan g1
significantly enhanced the permissiveness of GHOST cells for the R5X4 dualtropic virus. GHOST
cells expressing the CXCR4-g1 or CXCR4-g1/2 mutants were infected at higher rates by the
R5X4-dualtropic virus compared to cells expressing CXCR4-wt or CXCR4-g2 coreceptors.
Conclusion: Our present observations underscore a role for glycans present on the CXCR4
coreceptor in the entry process of HIV-1. The data will help to better understand the multifaceted
mechanism of HIV infection and the selective forces which drive HIV-1 evolution from mono- to
dual-tropism.
Background
The chemokine receptor CXCR4 belongs to the seven-
transmembrane-domain G-protein-coupled receptor fam-
ily and is one of the major coreceptors for human immu-
nodeficiency virus type 1 (HIV-1) [1,2]. The trimolecular
interaction between the HIV-1 receptor CD4, CXCR4 and
viral envelope proteins (gp120/gp41) is the first step in
HIV entry. Binding of gp120 to CD4 triggers conforma-
tional changes responsible for binding to the coreceptor.
Binding to coreceptor is followed by further conforma-
tional changes in the gp41 subunit which lead to mem-
brane fusion [3–5]. The N-terminal region and extra
cellular domains of CXCR4 are of particular importance
for the interaction with the third variable loop (V3) of
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HIV-1 gp120 [6–8]. While HIV-1 infection is dependent
on the interaction between at least three different mole-
cules, viral entry can be influenced by changes in the V3
region of gp120 or changes in the N-terminus and in the
second extracellular loop (ecl-2) of CXCR4. [9–12].
In general, amino acid exchanges within the gp120 V3
loop affects coreceptor usage, viral infectivity or can pro-
mote escape from neutralizing antibody. Due to amino
acid variations, the potential N-glycosylation sites within
the V3 loop region can be altered also. Thus, N-glycosyla-
tion is abolished or an additional glycosylation site is cre-
ated. The whole gp120 is a highly glycosylated protein
which contains between 23 and 25 potential sites for N-
glycosylation carrying glycan structures of the high man-
nose as well as complex type. Since gp120 contains such a
high amount of carbohydrate residues, more than 50% of
its molecular mass is represented by these sugars [13,14].
We have previously shown that the lack of some N-glycan
structures within the gp120 V3 loop of the HIV-1NL4–3
strain results in enhanced infectivity for CXCR4 express-
ing cells and in increased resistance to the inhibitor SDF-
1α. [15]. Viruses with functional glycosylation sites had
lower infectivity compared to the mutated deglycosylated
ones but were more resistant to neutralizing antibody.
These data were confirmed by studies of Pollakis et al. [16]
who have shown that the loss of the V3 loop N-Glycan at
position N301 had a major influence on CXCR4 corecep-
tor usage. These V3 loop sugars also play a role in the de-
velopment of viruses able to use CXCR4 in addition to
CCR5 [17]. Such an accumulation of CXCR4-usage is
linked to the development of viruses representing the SI
(syncytia inducing)-phenotype. The shift of the viral pop-
ulation from CCR5-monotropic viruses, which represent
the NSI-phenotype, to viruses of the SI-phenotype is a har-
binger of progression to AIDS [18–20]. These experiments
provide evidence for a role of V3 loop based sugars for the
development of viruses that can use CCR5 in addition to
CXCR4.
In the same way as gp120, the CXCR4 coreceptor is also
N-glycosylated. CXCR4 contains two potential N-glyco-
sylation sites g1 (aa pos. 11–13) and g2 (aa pos. 176–
178) within the N-terminal region and within the second
extracellular loop. Mutants of CXCR4 lacking N-glycosyla-
tion sites g1 and/or g2, which were expressed by insect
cells, exhibited a decreased binding activity and affinity
for the natural CXCR4 ligand SDF-1α [21]. More recently
it was reported that the loss of the N-terminal N-glycan g1
allows CXCR4 to serve as a coreceptor for some R5 mono-
tropic HIV-1 strains [22]. Thus, CXCR4 glycan g1 seems to
be involved in SDF-1 binding but is also involved in
masking the coreceptor function for CCR5-dependent vi-
ruses. Despite these results the influence of N-glycans on
HIV-coreceptor interaction is not fully understood. It re-
mains to be speculated whether N-glycosylation of
CXCR4 plays a role in the development of CXCR4-specific
viruses by adapting CCR5-dependent viruses step by step
to CXCR4.
In this study, we investigated the role of the N-linked gly-
cosylation of CXCR4 for viral infectivity. The N-glycosyla-
tion sites of CXCR4 were altered by amino acid exchanges
to generate genetically engineered mutants of CXCR4 with
and without N-glycosylation sites. To study infectivity,
GHOST cells expressing the CXCR4 mutants were infected
with recombinant viruses which only differ in the V3 loop
region and therefore in their CXCR4 and CCR5 coreceptor
usage. We found a significantly enhanced infectivity for
viruses able to use both coreceptors due to the lack of
CXCR4 glycosylation. The difference in CXCR4 glycosyla-
tion might lead to different distinct conformations, which
promote infection of dualtropic isolates. The presence of
CXCR4 in different glycosylated or partially glycosylated
forms might be relevant for the different antigenically dis-
tinct conformations of CXCR4 detected on primary cell
types [23] and for the differential recognition of CXCR4
by HIV-1 isolates based on a more accessible CXCR4 N-
terminus. The results provided will help us to better detail
the steps of CXCR4 – gp120 interaction and to further our
understanding on the multifaceted mechanism of HIV in-
fection on a molecular level.
Methods
Cells and culture conditions
Hela-P4 cells (provided by M. Dittmar, Heidelberg, Ger-
many) were grown in Dulbecco's modified Eagle's medi-
um (DMEM; PAA Laboatories, Linz, Austria) containing
10% fetal calf serum (FCS; Biochrom KG, Berlin, Germa-
ny). The human osteosarcoma cell line (GHOST; provid-
ed by D. Littmann, [36]) and the amphotropic helper-free
packaging cell line Phoenix (provided by G. Nolan, Stan-
ford, USA) were both cultured in DMEM supplemented
with 10% FCS. GHOST cells expressing human CD4 were
grown in medium supplemented with 500 µg/ml G418
(Life Technologies, Karlsruhe, Germany). GHOST cells ex-
pressing CD4 and the CXCR4 coreceptor were grown in
medium supplemented with G418 and 1 µg/ml puromy-
cin (Sigma, Deisenhofen, Germany).
Recombinant HIV-1 constructs
For infection assays we have used recombinant viruses
showing X4, R5 and R5X4 tropism differing in the V3 loop
region only. We used X4-tropic NL4-3 or R5X4- and R5-
tropic NL4-3 mutants which were constructed by replac-
ing the V3 region within the recombinant retroviral vector
pNL4-3BstII. By replacing the V3 region against the V3
loop region from two primary isolates PI-991 and PI-952
two recombinant NL4-3 mutants were generated showing
R5 and R5X4 tropism (R5-monotropic, NL-991; R5X4-du-BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/31
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altropic, NL-952). The method on how to replace the V3
region within the pNL4-3BstII vector is described in its
full details by Polzer et al. [15].
Retroviral vector DNA of the three different recombinant
HIV clones was purified from bacteria (strain XL-1 blue,
Life Technologies) using a plasmid purification kit accord-
ing to the manufacturer's recommendations (Macherey &
Nagel NucleoSpin Plasmid, Düren, Germany). Purified
DNA resuspended in FuGENE-6 transfection reagent (Ro-
che, Germany) at 1 µg/100 µl was used for transfection of
Hela-P4 cells. Cells were cultivated up to 4 days post trans-
fection in DMEM. Virus production was measured by a
standard p24 enzyme-linked immunosorbent assay (ELI-
SA) based on reagents and the protocol provided by the
European program EVA (Centralized Facility for AIDS Re-
agents, Hertfordshire, UK). Hela-P4 supernatants contain-
ing equal amounts of infectious virus, standardized for
equal amounts of p24 antigen, were used for the infection
of GHOST target cells expressing human CD4 and the
CXCR4 glycosylation mutants.
CXCR4 glycosylation mutants
To generate CXCR4 mutants differing in N-glycosylation
we used pcDNA3 (Invitrogen) CXCR4 expression vectors
provided by M.T. Dittmar. CXCR4 mutations were in-
duced by site-directed mutagenesis using a QuickChange
mutagenesis kit (Stratagene, Heidelberg, Germany). For
each mutation two polyacrylamide gel-purified oligonu-
cleotides were used and mutations were induced accord-
ing to manufacturer's instruction. In brief, the two primers
containing the point mutations, each complementary to
opposite strands, were annealed to the denatured plasmid
DNA. After adding DNA polymerase, in-vitro DNA syn-
thesis will generate mutated plasmid copies made of non-
methylated dsDNA. Non-methylated DNA is resistant to
Dpn1 enzyme cleavage. Thus, the parental plasmid DNA
can be digested with DpnI. This primer-based mutagene-
sis procedure selects for the in-vitro generated mutated
plasmid copy. The presence of each point mutation and
the absence of other mutations were confirmed by se-
quence analysis (CEQ2000 DNA Analysis System, Beck-
man Coulter, Germany). Mutated CXCR4 genes were
cloned into the unique EcoRI restriction site of the
pBABE-puro vector [36,37].
To establish coreceptor expressing GHOST cells we used
the Phoenix packaging cell line to generate infectious
MMLV supernatants. Phoenix cells were seeded in 6-well
culture dishes and transfected with pBABE-CXCR4 plas-
mids using the FuGENE-6 transfection method as de-
scribed above. Three days post infection, viral
supernatants containing infectious MMLV particles were
harvested and diluted 1:2 in DMEM supplemented with
polybrene (8 µg/ml; Sigma, Germany). GHOST cells cul-
tured in 48-well dishes were incubated with the MMLV su-
pernatants. Three days post infection puromycin was
added (1 µg/ml) and GHOST cells were cultured up to
two weeks for puromycin selection. After two weeks, cell
clones were isolated and cultivated for another two weeks.
Coreceptor surface expression of CXCR4 and mutated
CXCR4 was determined by fluorescent antibody staining
using the conformation-dependent phycoerythrin labeled
monoclonal antibodies (mAbs) 12G5 [38] (Pharmigen,
Hamburg, Germany). Cells were washed twice with phos-
phate-buffered saline (PBS) containing 1% FCS and
0.05% sodium azide at 0°C. GHOST cells (1.0 × 106/ml)
were stained using 20 µl of the 12G5 mAbs solution for 30
min, After washing three times with PBS/1% FCS/0.05%
sodium azide, FACS analysis was carried out using a FAC-
SCalibur (Becton Dickinson, Heidelberg, Germany) flow
cytometer.
HIV-1 infection studies
To perform HIV-1 infection studies GHOST cells stablely
expressing wild-type or mutant CXCR4 were seeded in 96-
well tissue culture dishes (1.0 × 103 to 3.0 103 cells per
well) and were infected with virus standardized for p24
antigen levels (NL4-3, 0,05 ng p24/well; NL-991, NL-952,
0,05 ng p24/well). After 18 h cells were washed three
times with PBS, 200 µl DMEM supplemented with 0.5%
FCS. Viral production was monitored on days 2, 3, 4, 6, 8
and 12 by a standard p24 antigen ELISA.
HIV-1 p24 assay
For the detection of p24 antigen, 96-well plates (Max-
isorb, Nunc) were coated with anti-p24 peptide-specific
goat antiserum D7320 (Biochrome, Germany) diluted
1:100 in 150 mM NaHCO3 (pH 8,5). Plates were stored
over night at 4°C, washed 6 times with PBS/Tween20
(0,05%) and blocked using PBS/Tween20 buffer contain-
ing 10% FCS (1 h, RT). After FCS blocking, plates were
washed 2 times and cell culture supernatants were added
to the wells in a final volume of 100 µl. After 1 h at room
temperature, plates were washed 6 times with PBS/
Tween20 and 100 µl anti-p24 rabbit antiserum diluted
1:2000 in PBS/Tween20/FCS buffer was added to each
well (anti-p24 rabbit serum was provided by H.-G. Kräus-
slich, ZMBH Heidelberg). Bound rabbit antibody was de-
tected with secondary anti-rabbit IgG-specific antibody
conjugated to alkaline phosphate using p-nitrophenyl-
phosphate (Bio-Rad alkaline detection kit) as a substrate.
The assay was standardized using the p24 antigen stand-
ard provided by the National Institute for Biological
Standards and Control (NIBSC, Herts, UK). The p24
standard was diluted in PBS/Tween20/FCS and was ap-
plied to each well at 200, 67, 22, 7.4, 2.5, 0.8 and 0,27 ng/
ml concentrations. The linear range of the p24 assay was
between OD405nm = 0,2–1,5 [(OD405nm – 0,1) / 0,04
= ng p24].BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/31
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Results
Construction of CXCR4 mutants
CXCR4 contains two potential N-glycosylation sites at
amino acid position 11–13 (NYT) and 176–178 (NVS)
(Fig. 1a). To generate mutants of CXCR4 differing in N-
glycosylation we have introduced point mutations chang-
ing the coding sequence for asparagine, threonine or ser-
ine into the coding sequence for glutamine and alanine
(Fig. 1b). Using the pBABE-puro cloning and expression
system GHOST.CD4 cells were transfected to express wild-
type CXCR4 (CXCR4+g1g2) or mutated CXCR4 lacking g1
and/or g2 (CXCR4-g1, CXCR4-g2, CXCR4-g1g2). CXCR4
expression was monitored by FACS analysis using the
CXCR4-specific antibody 12G5 (Fig. 2). CXCR4 wt
(CXCR4+g1g2) was set to 100% and both CXCR4-g2 mu-
tants showed identical CXCR4 expression levels. In rela-
tion to GHOST.CD4.CXCR4+g1g2 cell line. CXCR4
expression was reduced by 20% for the two CXCR4-g1
mutants and by 15% for the CXCR4-g1g2 mutant. Be-
tween mutants lacking g1 or g2 but differing in the first or
third position of the glycosylation site (i.e. N11Q versus
T13A, Fig. 1b), we observed no significant difference in
CXCR4 expression levels.
Construction of recombinant viruses differing in corecep-
tor usage
We have established a cloning system based on the NL4-3
virus that allows the exchange of the gp120 V3 loop. Two
V3 sequences taken from a R5- and a R5X4-tropic primary
isolate (PI-991, PI-952) (Fig. 3a) were introduced into the
NL4-3 env gene (Fig. 3b). The resulting NL4-3 env – V3
loop chimeras (NL991, NL-952), only differing in the V3
loop sequence, showed exactly the phenotypes of the orig-
inal primary isolate. The exchange of the V3 loop was suf-
ficient to change the original NL4-3 phenotype from X4-
to R5-tropism (NL-991) and from X4- to R5X4-dualtro-
pism (NL-952). The three recombinant viruses NL4-3, NL-
991 and NL-952 (Fig. 3c) were used for the infection of
the cells expressing the various CXCR4 g1/g2 mutants.
The role of CXCR4 glycans for HIV infection
GHOST.CD4 cells expressing the various CXCR4 glyco-
sylation mutants were infected with equal amounts of
NL4-3, NL-911 and NL-952 virus. Virus supernatants, de-
rived form HelaP4 cell cultures, were standardized based
on the level of p24 antigen. To study differences in
CXCR4-specific infection the various GHOST.CXCR4 cell
lines were infected with an equivalent of 0,5 ng of p24 for
each of the three viruses. Infection of GHOST cells with
NL4-3 using an equivalent of 0,5 ng p24 leads to 100% in-
fection within the first two days (data not shown). There-
fore, NL4-3 infection studies shown (Fig 4a) were carried
out with 0,05 ng p24 for each of the 96-wells. All experi-
ments were carried out in triplicate.
To study differences in permissiveness of the various
GHOST cell lines viral replication of NL4-3, NL-991 and
NL-952 was monitored over a period of 12 days (Fig.
4a,4b,4c). The results demonstrate that cells expressing
the CXCR4 mutants were infected at similar rates by NL4-
3 and we observed no differences in permissiveness for
cells expressing CXCR4 with or without g1 and/or g2.
Thus the lack of g1 or g2 on CXCR4 did not influence in-
fectivity for the X4-monotropic strain NL4-3. Both sugars
also had no effect on cell permissiveness for the R5-mono-
tropic NL-911 virus (Fig. 4c). Thus, lack of g1 and/or g2
on CXCR4 does not lead to a shift of the coreceptor spe-
cificity to allow CCR5-dependent viruses the entry via one
of the CXCR4 coreceptor mutants. In our experiments no
evidence was provided that a potential binding epitope on
CXCR4 for CCR5-dependent viruses is masked by glycans
g1 or g2.
Interestingly, the infection studies of GHOST cells ex-
pressing the various CXCR4 mutants with the dualtropic
virus NL-952 revealed a significantly enhanced permis-
siveness for NL-952 due to the lack of g1 (Fig 4b). Cells ex-
pressing CXCR4-g1 (N11Q, T13A) or CXCR4-g1g2
(N11Q/N176Q) were infected more efficiently by NL-952
compared to those cells expressing CXCR4+g1 (wt,
N176Q, S178A). Although the CXCR4 expression level of
the three GHOST.CD4.CXCR4-g1 cell lines (N11Q, T13A,
N11Q/N176Q) was significantly lower (Fig. 2), their per-
missiveness for NL-952 was higher (Fig. 4b). By testing all
the various cell lines we observed a clear cut between
higher permissiveness of the CXCR4-g1 and lower permis-
siveness of CXCR+g1 expressing cells for the dualtropic
NL-952 virus.
In general, viral replication needs 3 days for a complete
replication cycle. Therefore, the amount of p24 present on
day three represents rates of single round infection and is
a direct correlate for permissiveness. Using the amount of
0,5 ng p24 for infection of cells with NL4-3 leads to com-
plete infection reaching the maximum, the p24 plateau at
OD 1,2 (= 27,5 ng p24) within 48 h post infection (data
not shown). Since NL4-3 infection was complete at day
two, permissiveness of all cell lines for NL4-3 was set to
100%. For NL-911, no infection was observed over the
hole time period of 12 days. Therefore, the permissiveness
of all cell lines for NL-991 was set to 0%. Compared to the
two viruses NL4-3 and NL-911 the permissiveness of cells
for NL-952 was 50% for all of the three CXCR4-g1 express-
ing cell lines in contrast to the two CXCR4-g2 (N176Q or
S178A) cell lines who showed a lower permissiveness of
20% and 10%, respectively. However, permissiveness of
CXCR4-g1 cells for NL952 was about 300% higher com-
pared to CXCR4-g2 (S178A) and about 400% higher com-
pared to CXCR4-g2 (N176Q) or CXCR4-wt for infection
by the same virus (NL-952).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/31
Page 5 of 11
(page number not for citation purposes)
Figure 1
CXCR4 extracellular domains and CXCR4 mutants generated. A, two recognition sites for N-linked glycosylation, 
designated g1 (aa (NYT, pos. 11–13) and g2 (aa NVS, pos. 176–178) are located in the extracellular CXCR4 domains. B, by 
replacing the first amino acid N against Q and the third amino acid S against A a set of five CXCR4 mutants lacking g1, g2 or 
both glycans were generated. Amino acids: A, alanine; N, asparagine; Q, glutamine; S, serine; T, threonine; V, valine; Y, tyrosine.
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In the experiments shown we have analyzed the role of
the CXCR4-based N-linked glycans for viral infection. Per-
missiveness of GHOST cells for the dualtropic virus NL-
952 was enhanced due to the expression of the CXCR4-g1
mutants whereas permissiveness for the NL4-3 and NL-
911 viruses was not affected by CXCR4-based glycans g1
or g2.
Discussion
CXCR4 is expressed on a variety of cells and is one of the
two major coreceptors for HIV. CXCR4 is preferentially
present on T lymphocytes and the use of this coreceptor is
correlated with a progression of the disease and the devel-
opment of AIDS symptoms. Therefore it is important to
study how HIV accumulates coreceptor usage and is shift-
ing from the R5-monotropic to the R5X4-dualtropic phe-
notype.
Recently it was shown that CXCR4 can be found in anti-
genically distinct conformations on primary cell types
[24]. The CXCR4 coreceptor is subject to a number of
modifications like phosphorylation [25] and can also be
sulfated [26]. Moreover, CXCR4 is N-glycosylated, a major
modification of proteins, generally involved in stabiliza-
tion of protein conformation, the masking of binding
epitopes [15] and the shielding of antigenically important
epitopes [27]. By using genetically engineered mutants of
CXCR4 differing in the presence of the N-linked glycans
g1 and g2, we established that there are differences in the
relative permissiveness of GHOST cells for the dualtropic
virus NL-952. A significant difference in permissiveness
was observed between all cells expressing CXCR4-g1 and
all cells expressing CXCR4+g1 mutants. The data suggest
that g1 might mask a region on CXCR4 that plays a role in
the interaction between NL-952 and CXCR4. The extracel-
lular domains of CXCR4 contain a high number of nega-
tively charged amino acids in contrast to CCR5 (Fig 5).
Glycan g1 is located in the N-terminal part of the CXCR4
coreceptor (pos 11–13) and is next to amino acids Glu14,
Glu15 and Glu 32, which are important for CXCR4 func-
tion [28]. These amino acids in the N-terminal region and
Asp97 within the first extracellular loop might be in-
volved in the binding of positively charged amino acids
present in X4-tropic V3 loop sequences. If g1 is involved
in the interaction between negatively and positively
charged amino acids it probably has an impact on the in-
fectivity of CXCR4-dependent viruses.
To study the interaction of HIV with its CXCR4 coreceptor
we have used recombinant viruses with X4, R5 and R5X4
tropism based on NL4-3. These viral recombinants have
an identical genetic background and only differ in their V3
region. The NL4-3 V3 region was replaced against the V3
region of two primary isolates, which showed R5-mono-
and R5X4-dualtropism. In addition to the data on CXCR4
mutants, we have shown again, that the V3 loop is the
most important region within gp120 to determine viral
tropism. By replacing only the NL4-3 V3 loop, the original
coreceptor phenotype of the two primary isolates was
transferred successfully to the NL4-3 virus. Beside the dif-
ference in the V3 loop amino acid sequence the most sim-
ple but fundamental difference of these viruses is the
presence of positively and negatively charged amino acids
in the V3 region. A comparison of charged amino acids for
the three V3 loop and the CXCR4 and CCR5 coreceptors
is given in Fig 6. The NL4-3 virus contains 12 (5K/7R)
lysine and arginine residues in its V3 region and 11 (5K/
6R) of these amino acids can be found in the R5X4-dual-
tropic NL-952 V3 region. The lowest number of arginine
and lysine residues was found in the R5-monotropic NL-
991 with only 1 lysine and 6 arginine residues. It is known
that the overall positive charge of the V3 loop is correlated
to the usage of CXCR4 and CCR5 [29]. A high positive
charge between +7 and +9 promotes CXCR4 usage where-
as a charge between +2 and +3 promotes use of CCR5.
Many viruses have an overall charge between these two ex-
tremes and therefore can use both coreceptors. Although
some examples like NL-952 (+6), exist, the exact predic-
Figure 2
CXCR4 cell surface expression. The CXCR4 coding 
sequence was mutated in the pcDNA3.1 plasmid, cloned into 
pBABE-puro and finally expressed in GHOST.CD4 cells. Cell 
surface expression was monitored by flow cytometry using 
phycoerythrin labeled anti-CXCR4 mAb 12G5. Coreceptor 
expression is expressed as % of CXCR4 wt expression of 
GHOST.CD4.CXCR4 cells. Error bars are calculated based 
on three independent experiments.
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Figure 3
Construction of NL4-3 mutants differing in coreceptor usage. A, Amino acid V3 loop sequence of the NL4-3 labora-
tory strain and of two primary isolates PI-952 (R5X4-dualtropic) and PI-991 (R5-monotropic) of different phenotype. B, V3 
loop regions of patient isolates were generated by PCR amplification followed by a second PCR. In the second PCR amplifica-
tion silent mutations were introduced to generate the BglII and NheI restriction sites. PCR fragments were cloned into 
pUCenv-deltaV3 and the NL4-3 env – V3 loop chimera was cloned into the pNL4-3Bst retroviral vector as a BstEII/BamHI 
fragment. C, This V3 cloning procedure was carried out to generate mutants of NL4-3, designated NL-952 and NL-991, con-
taining the V3 loop and the coreceptor phenotype of the of the original primary isolates. NL4-3, X4-monotropic; NL-952, 
R5X4-dualtropic; NL-991, R5-monotropic.
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Figure 4
Virus replication and CXCR4 glycosylation. GHOST 
cells expressing CXCR4 wt or CXCR4-g1, -g2 or -g1/g2 
were infected with equal amounts of (A) the X4 tropic strain 
NL4-3 (0.05 ng p24 / 3 × 10e3 cells), (B) the R5X4 dual-
tropic virus NL-952 (0.5 ng p24 / 3 × 10e3 cells) and (C) the 
R5 tropic HIV-1 NL-991 (0.5 ng p24 / 3 × 10e3 cells. Virus 
production was measured by a standardized p24 antigen 
ELISA [(OD405nm – 0,1) / 0,04 = ng p24, linear range 
OD405m 0,2–1,5]. Values are calculated based on two inde-
pendent experiments. White symbols GHOST.CD4 cells 
expressing CXCR4 lacking g1, black symbols GHOST.CD4 
cells expressing CXCR4 containing g1.
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Figure 5
Charged amino acids in the extracellular domains of 
CXCR4 and CCR5. The diagramm shows a schematic rep-
resentation of the extracellular domains of CXCR4 and 
CCR5. Indicated are positively and negatively charged amino 
acids and the glycans attached to asparagine residues. Symbol 
plus, lysine (K) and arginine (R) amino acid residues; symbol 
minus, glutamic (E) and aspartic (D) acid amino acid residues.
Figure 6
Comparison of charged amino acids between core-
ceptors and viral V3 loops. This comparison shows the 
number of charged amino acids in the extracellular domains 
of CXCR4 and CCR5 and the number in the V3 loop of the 
three viruses NL4-3, NL-952 and NL-991. Symbol plus ( ), 
lysine (K) and arginine (R) amino acid residues, Symbol minus 
( ), glutamic (E) and aspartic (D) acid amino acid residues. 
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tion of dual tropism based on the overall charge of the V3
region is not always possible [30,31].
Looking on charged amino acids, the two CXCR4-depend-
ent viruses (NL4-3 and NL-952) have a similar number
(12 and 11, respectively) of positively charged amino ac-
ids. Therefore they might have the prerequisite to bind
CXCR4. Looking on negatively charged amino acids, the
two viruses NL-952 and NL-991 share 5 negative charged
amino acids that might be relevant for CCR5 binding.
Thus, the NL-952 virus that has both of these prerequisites
is able to bind both coreceptors. The question was: Do
carbohydrates play a role in the interaction between
gp120 and CXCR4? For the NL4-3 strain we have shown
that the lack of the V3 loop glycan g15 on gp120 en-
hanced CXCR4-specific infection[15]. For NL-952 we
showed that g15 is responsible for CCR5 binding. NL-952
mutants lacking g15 within their V3 loop were unable to
infect CCR5 expressing cells but the ability to infect
CXCR4 expressing cells remained [32]. From these exper-
iments we have postulated that the glycan structure on
gp120 is shielding some positively charged amino acids.
This would explain why NL-952 can bind CCR5 and why
it looses CCR5 binding activity when g15 is missing. In
case of g15 deficiency the positive amino acids might be
exposed and not masked by the g15 sugar. Thus, the max-
imal positive charge of the V3 loop is presented. Under
these conditions CXCR4 binding is possible, but not
CCR5-dependent infection. From these experiments we
hypothesize a role for glycans in masking positively
charged amino acids.
The function of the CXCR4 g1 glycan might be similar to
the function postulated for the g15 V3 loop glycan. A neg-
atively charged CXCR4 coreceptor, as shown in Fig 5, is a
good target for viruses presenting a highly positively
charged V3 loop (Fig 6) or CXCR4 positively charged lig-
ands like SDF-1 [33]. If g1 is masking some of the posi-
tively charged amino acids on CXCR4 it is conceivable
that the net charge of CXCR4+g1 is more negative com-
pared to the net charge that is present on deglycosylated
CXCR4-g1. The lack of g1 would therefore reduce the
overall negative charge of the CXCR4 coreceptor. As a con-
sequence, the dualtropic virus can bind to the deglyco-
sylated CXCR4 coreceptor much more efficiently. In the
situation where g1 is present, some of the positive amino
acids are masked and the coreceptor is presenting its max-
imum of negative charged amino acids. Such a highly neg-
atively charged coreceptor surface might be less accessible
for NL-952 that has a net charge of +6 compared to NL4-
3 with a net charge of +9. The masking of amino acids by
g1 has no function on the infection by NL-991 as shown
in our experiments. This virus has probably no prerequi-
sites, no high number of positively charged amino acids,
which allows CXCR4 interaction. An exposure of a nega-
tively charged surface on CXCR4 with or without glycan
g1 might be not sufficient to allow infection of a R5-
monotropic virus with a low V3 net charge of +2. It would
be interesting to study changes of coreceptor specificities
due to the insertion of argine and lysine residues in the V3
loop of CCR5-dependent viruses. The insertion of posi-
tively charged residues in the NL-991 sequence will prob-
ably lead to a virus that can use deglycosylated CXCR4
more efficiently than the glycosylated wt CXCR4. To test
the theory of positively charged amino acids and masking
of these residues by carbohydrates needs further investiga-
tions using more studies on recombinant mutants of vi-
ruses and coreceptors.
An important question is: Are mutants or deglycosylated
forms of the CXCR4 coreceptor present in vivo? Studies by
Baribaud et al. [23,24] have shown that the CXCR4 core-
ceptor can be identified on different primary cell lines in
different antigenically distinct conformations. The study
provided evidence that CXCR4 is present in different
forms in vivo and that the heterogeneity observed is cell
type dependent. N-Glycosylation is also cell type depend-
ent, thus it is conceivable that the various forms of CXCR4
can be the result of changes in N-glycosylation. In most
studies differences in CXCR4 conformation can be in-
ferred by using monoclonal antibodies to CXCR4. The
12G5 antibody was shown to discriminate between
CXCR4 conformations. Neutralization of viruses by 12G5
mab was shown to be cell type dependent, allowing virus-
es to escape from 12G5 mab neutralization [34]. Thus, the
epitope for 12G5 mab shows heterogeneity due to the cell
line that expresses CXCR4. We also have observed a differ-
ence in binding of the mab 12G5 to CXCR4. In our exper-
iments CXCR4 was produced by identical GHOST cells,
thus the difference observed in 12G5 binding can be inter-
preted as an effect of the g1 sugar.
We propose, that CXCR4 in a partially or non-glycosylat-
ed form is a better ligand for dualtropic viruses. Masking
the CXCR4 coreceptor by the carbohydrate structure g1
might block the interaction between the NL-952 and
CXCR4+g1 to some extend. Since the viruses used in our
study only differ in the gp120 V3 loop region, the en-
hanced binding to the various CXCR4-g1 mutants can be
interpreted as an effect of the mutated coreceptors and the
V3 loop.
Our hypothesis on the masking of a CXCR4 epitope that
might be presented by positively charged amino acids is in
part in agreement with data on genetically engineered mu-
tants that differ in the V3 loop glycosylation [35,11,15,17]
and with data observed by studying glycosylation mutants
of coreceptors [22,28]. We know that the experiments
provided are not a direct proof of this hypothesis, but oneBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/31
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more step is made to unscramble the complex interactions
of HIV-1 variants with their various coreceptors.
Conclusions
Our present observations underscore a role for glycans
present on the CXCR4 coreceptor in the entry process of
HIV-1. The data will help to better understand the multi-
faceted mechanism of HIV infection and the selective forc-
es that drive HIV-1 evolution from R5 mono- to R5X4
dual-tropism.
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